Nasdaq · CIK 0001580149
BIVI BIOVIE INC.
Insider trading from SEC Form 4. Last filing Jan 9, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Signals
Open-market buys and sells at BIOVIE INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 26 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | James Paul Lang director | AGrant or award Stock Option (right to buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Jan 9, 2026 |
| Jan 5, 2026 | Amy Suzon Chappell director | AGrant or award Stock Option (right to buy)derivative | +57,500 | $0.00 | $0 | 57,500 | Jan 9, 2026 |
| Jan 5, 2026 | Kameel D. Farag director | AGrant or award Stock Option (right to buy)derivative | +57,500 | $0.00 | $0 | 57,500 | Jan 9, 2026 |
| Jan 5, 2026 | Michael Edward Sherman director | AGrant or award Stock Option (right to buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Jan 9, 2026 |
| Jan 5, 2026 | Joseph M Palumbo Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +132,000 | $0.00 | $0 | 132,000 | Jan 9, 2026 |
| Jan 5, 2026 | Cuong Do V President & CEO | AGrant or award Stock Option (right to buy)derivativeindirect: See Footnote | +665,300 | $0.00 | $0 | 665,300 | Jan 9, 2026 |
| Jan 5, 2026 | Sigmund Rogich director | AGrant or award Stock Option (right to buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Jan 9, 2026 |
| Jan 5, 2026 | Joanne Wendy Kim Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +110,100 | $0.00 | $0 | 110,100 | Jan 9, 2026 |
| Jan 5, 2026 | James Paul Lang director | AGrant or award Stock Option (right to buy)derivative | +330,500 | $0.00 | $0 | 330,500 | Jan 9, 2026 |
| Jan 5, 2026 | Sigmund Rogich director | AGrant or award Stock Option (right to buy)derivative | +141,100 | $0.00 | $0 | 141,100 | Jan 9, 2026 |
| Jan 5, 2026 | Michael Edward Sherman director | AGrant or award Stock Option (right to buy)derivative | +341,100 | $0.00 | $0 | 341,100 | Jan 9, 2026 |
| Aug 7, 2025 | Cuong Do V President & CEO | POpen-market purchase Common Stockindirect: See Footnote | +5,000 | - | - | 9,992 | Aug 13, 2025 |
| Aug 7, 2025 | Cuong Do V President & CEO | POpen-market purchase Warrants (right to buy)derivativeindirect: See Footnote | +5,000 | - | - | 5,050 | Aug 13, 2025 |
| Nov 20, 2024 | Sigmund Rogich director | AGrant or award Common Stock | +32,700 | $0.00 | $0 | 36,926 | Jan 7, 2025 |
| Nov 20, 2024 | Michael Edward Sherman director | AGrant or award Stock Option (right to buy)derivative | +56,900 | $0.00 | $0 | 56,900 | Jan 7, 2025 |
| Nov 20, 2024 | James Paul Lang director | AGrant or award Stock Option (right to buy)derivative | +61,600 | $0.00 | $0 | 61,600 | Jan 7, 2025 |
| Nov 20, 2024 | Robert J Hariri director | AGrant or award Stock Option (right to buy)derivative | +49,800 | $0.00 | $0 | 49,800 | Jan 7, 2025 |
| Nov 20, 2024 | Richard J Berman director | AGrant or award Common Stock | +34,200 | $0.00 | $0 | 40,643 | Jan 7, 2025 |
| Dec 20, 2024 | Joseph M Palumbo Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +15,417 | $0.00 | $0 | 15,417 | Jan 7, 2025 |
| Dec 20, 2024 | Joanne Wendy Kim Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +14,417 | $0.00 | $0 | 14,417 | Jan 7, 2025 |
| Dec 20, 2024 | Cuong Do V President & CEO | AGrant or award Stock Option (right to buy)derivativeindirect: See Footnote | +104,502 | $0.00 | $0 | 104,502 | Jan 7, 2025 |
| Dec 20, 2024 | James Paul Lang director | AGrant or award Stock Option (right to buy)derivative | +22,690 | $0.00 | $0 | 22,690 | Jan 7, 2025 |
| Dec 20, 2024 | Michael Edward Sherman director | AGrant or award Stock Option (right to buy)derivative | +23,325 | $0.00 | $0 | 23,325 | Jan 7, 2025 |
| Dec 20, 2024 | Sigmund Rogich director | AGrant or award Stock Option (right to buy)derivative | +22,070 | $0.00 | $0 | 22,070 | Jan 7, 2025 |
| Dec 20, 2024 | Robert J Hariri director | AGrant or award Stock Option (right to buy)derivative | +21,815 | $0.00 | $0 | 21,815 | Jan 7, 2025 |
| Dec 20, 2024 | Richard J Berman director | AGrant or award Stock Option (right to buy)derivative | +23,155 | $0.00 | $0 | 23,155 | Jan 7, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Richard J Bermandirector
- Amy Suzon Chappelldirector
- Cuong Do VPresident & CEO
- Kameel D. Faragcfo, officer, director
- Robert J Hariridirector, ceo, officer
- Joanne Wendy KimChief Financial Officer
- James Paul Langdirector
- Joseph M PalumboChief Medical Officer
- Sigmund Rogichdirector
- Michael Edward Shermandirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.